Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study
F Zustovich, L Landi, G Lombardi, C Porta… - Anticancer …, 2013 - ar.iiarjournals.org
Background: Bevacizumab has provided encouraging results in relapsed glioblastoma
multiforme (GBM). Pre-clinical and clinical investigations also showed that continuous low-
dose temozolomide has some antiangiogenic activity. Based on this evidence, a phase II
trial was designed to investigate an oral regimen of sorafenib, an oral multikinase inhibitor,
and metronomic temozolomide for relapsed GBM. Patients and Methods: Forty-three
patients (median age= 60.0 years) naive for antiangiogenic agents received 400 mg …
multiforme (GBM). Pre-clinical and clinical investigations also showed that continuous low-
dose temozolomide has some antiangiogenic activity. Based on this evidence, a phase II
trial was designed to investigate an oral regimen of sorafenib, an oral multikinase inhibitor,
and metronomic temozolomide for relapsed GBM. Patients and Methods: Forty-three
patients (median age= 60.0 years) naive for antiangiogenic agents received 400 mg …
Sorafenib plus daily low dose temozolomide for relapsed glioblastoma: A phase II study.
F Zustovich, L Landi, G Lombardi, L Galli… - Journal of Clinical …, 2011 - ascopubs.org
2080 Background: There are no phase III trials supporting the role of some treatment for
relapsed glioblastomas (GBMs). GBMs are very vascularized neoplasms thus
antiangiogenic therapies might obtain some antitumoral effects. Recently, an antiangiogenic
such as bevacizumab has given prior encouraging results in phase II studies and is under
phase III investigation. From phase II studies also low dose protracted temozolomide (LDPT)
seems to have some activity at relapse. Basing on these evidences we planned a phase II …
relapsed glioblastomas (GBMs). GBMs are very vascularized neoplasms thus
antiangiogenic therapies might obtain some antitumoral effects. Recently, an antiangiogenic
such as bevacizumab has given prior encouraging results in phase II studies and is under
phase III investigation. From phase II studies also low dose protracted temozolomide (LDPT)
seems to have some activity at relapse. Basing on these evidences we planned a phase II …